Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation

Koyuncu, Hakan; Şerefoğlu, Ege Can; Özdemır, Ahmet; Hellstrom, Wayne J.G.

doi:10.1038/ijir.2012.12

Cited by 39 publications

(23 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The fertility potential of a substantial number of men on paroxetine may be adversely affected by these changes in sperm DNA integrity (43,44). Manufacturer sponsored 2-year rat genetic toxicology studies of dapoxetine HCl at up to 0.25% of the diet, corresponding to a dose of 158 mg/kg/day, showed no effects on fertility, reproductive performance or reproductive organ morphology in male or female rats (45).…”

Section: New Therapeutic Targets and Emerging Drugsmentioning

confidence: 99%

Emerging and investigational drugs for premature ejaculation

McMahon

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

Over the past 20−30 years, the premature ejaculation (PE) treatment paradigm, previously limited to behavioural psychotherapy, has expanded to include drug treatment. Pharmacotherapy for PE predominantly targets the multiple neurotransmitters and receptors involved in the control of ejaculation which include serotonin, dopamine, oxytocin, norepinephrine, gamma amino-butyric acid (GABA) and nitric oxide (NO). The objective of this article is to review emerging PE interventions contemporary data on the treatment of PE was reviewed and critiqued using the principles of evidence-based medicine. Multiple well-controlled evidence-based studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in delaying ejaculation, confirming their role as first-line agents for the medical treatment of lifelong and acquired PE. Daily dosing of SSRIs is likely to be associated with superior fold increases in IELT compared to on-demand SSRIs. On-demand SSRIs are less effective but may fulfill the treatment goals of many patients. Integrated pharmacotherapy and CBT may achieve superior treatment outcomes in some patients. PDE-5 inhibitors alone or in combination with SSRIs should be limited to men with acquired PE secondary to co-morbid ED. New on-demand rapid acting SSRIs, oxytocin receptor antagonists, or single agents that target multiple receptors may form the foundation of more effective future on-demand medication. Current evidence confirms the efficacy and safety of dapoxetine, off-label SSRI drugs, tramadol and topical anaesthetics drugs. Treatment with α1-adrenoceptor antagonists cannot be recommended until the results of large well-designed RCTs are published in major international peer-reviewed medical journals. As our understanding of the neurochemical control of ejaculation improves, new therapeutic targets and candidate molecules will be identified which may increase our pharmacotherapeutic armamentarium.

show abstract

Section: New Therapeutic Targets and Emerging Drugsmentioning

confidence: 99%

Emerging and investigational drugs for premature ejaculation

McMahon

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…However, a few small studies have shown potential harmful effects of SSRIs on spermatozoon [22,23]. However, a few small studies have shown potential harmful effects of SSRIs on spermatozoon [22,23].…”

Section: Wish For Pregnancymentioning

confidence: 99%

Pharmacotherapy for premature ejaculation

Waldinger

2014

Current Opinion in Psychiatry

View full text Add to dashboard Cite

show abstract

“…Hypoactive desire and erectile dysfunction are also reported [43]. Of note, SSRIs must be used with caution in premature ejaculation patients who desire fertility, as these drugs are associated with impaired sperm parameters [44-46]. …”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Advances in treating premature ejaculation

Çayan

Şerefoğlu

2014

F1000Prime Rep

View full text Add to dashboard Cite

In spite of its high prevalence and long history, the ambiguity regarding the definition, epidemiology and management of premature ejaculation continues. Topical anesthetic creams and daily or on-demand selective serotonin reuptake inhibitor (SSRI) treatment forms the basis of pharmacotherapy for premature ejaculation today, in spite of low adherence by patients. Psychotherapy may improve the outcomes when combined with these treatment modalities. Tramadol and phosphodiesterase type 5 inhibitors have a limited role in the management of premature ejaculation. Further research is required to develop better options for the treatment of this common sexual disorder.

show abstract

Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation

Cited by 39 publications

References 36 publications

Emerging and investigational drugs for premature ejaculation

Emerging and investigational drugs for premature ejaculation

Pharmacotherapy for premature ejaculation

Advances in treating premature ejaculation

Contact Info

Product

Resources

About